Indication
Systemic lupus erythematosus
Systemic lupus erythematosus is a chronic, multisystem autoimmune disorder characterized by loss of immune tolerance, aberrant activation of B and T lymphocytes, and the production of pathogenic autoantibodies, most notably antinuclear antibodies. Read more about Systemic lupus erythematosus
382 drugs 179 manufacturers
Drugs that treat it
Common Systemic lupus erythematosus therapies.
DEPO-MEDROL (methylprednisolone acetate)
MEDROL (PAK) (methylprednisolone)
CORTROPHIN GEL (corticotropin)
MILLIPRED (prednisolone)
SOLU-MEDROL (PF) (methylprednisolone sodium succinate/PF)
SOLU-MEDROL (PF) (methylprednisolone sodium succinate/PF)
SOLU-MEDROL (PF) (methylprednisolone sodium succinate/PF)
SOLU-MEDROL (PF) (methylprednisolone sodium succinate/PF)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSystemic lupus erythematosus is a chronic, multisystem autoimmune disorder characterized by loss of immune tolerance, aberrant activation of B and T lymphocytes, and the production of pathogenic autoantibodies, most notably antinuclear antibodies.
It predominantly affects women of childbearing age and exhibits a relapsing and remitting course of widespread inflammation and immune-complex deposition.
Clinical manifestations are highly heterogeneous and can affect virtually any organ system, commonly presenting with constitutional symptoms, inflammatory arthritis, mucocutaneous lesions such as a malar rash, serositis, hematologic cytopenias, and potentially severe renal, neuropsychiatric, or cardiovascular complications.
- nih.gov
Systemic lupus erythematosus is a chronic, multisystem autoimmune disorder characterized by loss of immune tolerance, aberrant activation of B and T lymphocytes, and the production of pathogenic autoantibodies, most notably antinuclear antibodies It predominantly affects women of childbearing age and exhibits a relapsing and remitting course of widespread inflammation and immune-complex deposition
- nih.gov
Systemic lupus erythematosus is a chronic, multisystem autoimmune disorder characterized by loss of immune tolerance, aberrant activation of B and T lymphocytes, and the production of pathogenic autoantibodies, most notably antinuclear antibodies It predominantly affects women of childbearing age and exhibits a relapsing and remitting course of widespread inflammation and immune-complex deposition
- medlineplus.gov
Clinical manifestations are highly heterogeneous and can affect virtually any organ system, commonly presenting with constitutional symptoms, inflammatory arthritis, mucocutaneous lesions such as a malar rash, serositis, hematologic cytopenias, and potentially severe renal, neuropsychiatric, or cardiovascular complications
- nih.gov
Clinical manifestations are highly heterogeneous and can affect virtually any organ system, commonly presenting with constitutional symptoms, inflammatory arthritis, mucocutaneous lesions such as a malar rash, serositis, hematologic cytopenias, and potentially severe renal, neuropsychiatric, or cardiovascular complications
Personalize your experience
Follow Systemic lupus erythematosus and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.